The US state of Indiana is investing government funds in research into the potential therapeutic effects of psilocybin, the psychedelic substance found in magic mushrooms. Researchers are looking into applications for depression, anxiety, and post-traumatic stress disorder (PTSD), among other things.
That is striking, because psilocybin is still illegal in Indiana. Moreover, the substance is federally listed in Schedule I. Nevertheless, the state sees sufficient scientific potential to financially support further research.
Special Research Fund
Indiana established the Therapeutic Psilocybin Research Fund in 2024. Research into psilocybin is supported by that fund.
One of the scientists involved is Helen Fox, Professor of Psychiatry at the Indiana University School of Medicine. Researchers are looking at, among others, people with treatment-resistant depression: patients for whom existing treatments yield insufficient results.
According to the researchers involved, the initial research results are cautiously considered promising. However, this does not mean that efficacy has already been definitively established. Larger and longer-term clinical trials are required for that.
Psychedelics remain banned
In doing so, Indiana is choosing a striking middle ground. The state is not legalizing psilocybin, but is simultaneously making funds available to investigate its medical potential.
Cannabis for recreational use also remains prohibited in Indiana. As a result, the state lags behind several other US states in terms of drug policy, while taking a more active position regarding psychedelic research.
The interest fits within a broader development in the United States. Universities, companies, and governments are increasingly investigating whether psychedelics can be used under controlled conditions within mental healthcare.
Ready to see how Snowflake works?
The fact that Indiana is investing government funds in psilocybin research shows how quickly the position of psychedelics is changing. Psilocybin remains banned, but is simultaneously being seriously investigated as a potential treatment for severe mental health issues. The upcoming studies must clarify whether the initial positive signs hold up.
Source: axios.com
